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Inﬂammatory myoﬁbroblastic tumor (IMT) is a neoplasm of low
malignant potential (Shintaku and Fukushima, 2006). It is composed
of mesenchymal cells showing differentiation toward myoﬁbroblast or
ﬁbroblast and is usually associated with an inﬂammatory cell inﬁltra-
tion within the lesion (Cofﬁn et al., 1995; Pettinato et al., 1990). IMT
was ﬁrst described in the lung and most commonly involves that
organ, however, it may occur in a wide range of organs including
the retroperitoneum, mesentery, extremities, head, neck, omentum,
and genitourinary system (Cofﬁn et al., 2007; Olgan et al., 2011). It
has been previously referred to as inﬂammatory pseudotumor, plasma
cell granuloma, or pseudosarcomatous myoﬁbroblastic proliferation
(Shintaku and Fukushima, 2006; Cofﬁn et al., 2007; Rabban et al.,
2005). A triad of ﬁndings deﬁne IMT: 1) myoﬁbroblastic proliferation
lacking nuclear atypia; 2) lymphoplasmacytic inﬁltrate; 3) variable
myxoid stromal background (Rabban et al., 2005). IMT was considered
a reactive or inﬂammatory lesion, but cytogenetic studies have shown
genetic rearrangements of the anaplastic lymphoma kinase (ALK)
gene located in the chromosomal region 2p23 of this lesion conﬁrmed
its true neoplastic nature (Olgan et al., 2011; Rabban et al., 2005;⁎ Corresponding author. Fax: +1 410 614 8718.
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mately 50% of IMT and is considered a useful diagnostic marker
(Shintaku and Fukushima, 2006). The prognosis of IMT is generally fa-
vorable, but can vary. Rare cases are known to involve malignant trans-
formation. Unfortunately, there are no deﬁnitive morphological criteria
to predict an aggressive clinical behavior in these types of tumors. The
presence of large cells with “ganglion-like” features suggests a more
aggressive clinical behavior (Shintaku and Fukushima, 2006).
Uterine involvement by IMT is rare. To our knowledge only 12 cases
has been reported in the literature (Shintaku and Fukushima, 2006;
Olgan et al., 2011). The histologic appearance of uterine IMT is similar to
that of extra-uterine IMT. Clinically, the majority of IMT's are benign,
but they require adequately surgical removal because there is a propensi-
ty for local recurrence. The cases of IMT reported in the literature involv-
ing gynecologic organs are conﬁned to the uterus. To our knowledge, this
is the ﬁrst report of IMT that spread beyond the uterus to involve other
gynecologic and intraperitoneal organs.
Case report
A 30-year-old Para 0 woman started to experience irregular men-
strual periods in 2010. Physical examination including pelvic exam
wasnormal. A pelvic ultrasound from2010 showed a retroverted uterus
thatmeasured 6.0 × 4.5 × 1.6 cm. The endometriummeasured 11 mm
with a cystic area measuring 11.5 mm. The right ovary measured
2.4 × 1.9 × 1.7 cm. The left ovary measured 2.5 × 1.8 × 1.6 cm. She
was started on depo-provera with resolution of symptoms. In June of
2012, she developed left lower quadrant pain, post-coital bleeding and
irregular menstrual periods that were heavy associated with passage
of blood clots and soaking of pads. A pelvic ultrasound showed a uterus
thatmeasured 8.4 × 4.5 × 5.3 cm. Endometriumwas 15 mmwithﬂuid
within the lower portion of the uterus. The right ovary measured
2.9 × 2.4 × 1.9 cm. The left ovary measured 2.5 × 1.8 × 1.8 cm
with an echogenic area surrounding the left ovary measuring
7.2 × 6.2 × 3.8 cm. A CT scan of the abdomen and pelvis with PO
and IV contrast showed a complex, left adnexal mass that measured
6.3 × 5.0 × 6.1 cm. Multiple, small, low-density masses were pres-
ent within the right pelvis and midline location measuring less
than or equal to 1.8 cm in size. Uterus was not enlarged. No lymph-
adenopathy was appreciated. PAP smear from April 2012 was negative.
She underwent an examination under anesthesia with cystoscopy,
proctoscopy, cervical polypectomy, hysteroscopy, dilatation and curet-
tage, laparoscopy, and excision of pelvic masses in July of 2012 at
an outside facility. Intraoperative ﬁndings revealed polypoid masses
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Fig. 1.Thehistologyof the tumor from this case. (A) A lowmagniﬁcation show fascicles of spindle cell neoplasmwith hypercellular area alternatingwith hypocellular and edeomous tumor
region. (B and C) A medium magniﬁcation reveals spindle cells intermingled with prominent inﬂammatory cell inﬁltrates. (D) A high magniﬁcation demonstrates ﬁbroblast-like tumor
cells with abundant eosinophilic cytoplasm. Inﬂammatory cells are clearly evident.
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masses in the pelvis adherent to the bowel and mesentery. Masses
were noted bilaterally in the pelvis, and within the cul-de-sac (see
Image 1). There was a 2.3 cm pedunculated mass extending off the in-
ferior portion of the cervix with multiple smaller masses extending
from the anterior lip of the cervix. These masses were friable and bled
easily. The rectumwas free of disease up to 17 cm. Cystoscopywas nor-
mal. Pathology revealed an IMT. Immunohistochemical stains were
performed to conﬁrm the diagnosis. The tissue specimen was smooth
muscle actin: negative, muscle speciﬁc: negative, Desmin: positive,
ALK-1: negative, HMB-45: negative, CD34: negative, CD117: negative,
Cathespsin-k: positive, ER: positive, PR: positive (see Fig. 1).
The patient underwent an examination under anesthesia with ex-
ploratory laparotomy, modiﬁed radical hysterectomy with bilateral
salpingo-oopherectomy, resection of left pelvic sidewall mass, resection
of pelvic peritoneum, resection of rectosigmoid implants, resection of
bladder peritoneum, and cystoscopy. All visible disease was removed.
The patient's post-operative coursewas uneventful. Shewas discharged
home on postoperative day #2. She recovered well from the surgery.
The ﬁnal pathology conﬁrmed the diagnosis of IMT. Pathology revealed
that the tumor involved the uterus, cervix, bilateral fallopian tubes and
ovaries, left pelvic sidewallmass, bladder and rectosigmoid peritoneum,
and parametrium. The histology of the tumor is shown in Fig. 1. At the
present time, the patient is six months out from surgery and has no
evidence of disease.Discussion
IMT of the uterus is rare. Although the lung is themost common site
of occurrence, it does occur in diverse extrapulmonary locations (Cofﬁn
et al., 1995). Regardless of the site of origin, IMT has a predilection for
younger patients (Cofﬁn et al., 1995; Olgan et al., 2011). The age range
of women affected by IMT was 6–63 years of age, with the majority of
women being diagnosed in the ﬁrst four decades of life (Shintaku and
Fukushima, 2006; Olgan et al., 2011; Rabban et al., 2005; Azuno et al.,
2003; Gilks et al., 1987; Gupta et al., 2011). Symptoms at presentationwere varied including intermittent abdominal pain, dyspareunia, ab-
dominal distention, new onset menorrhagia, fever, and weight loss.
Surgical approach to this disease varies based on the extent of dis-
ease, age of the patient, and suggested pathologic ﬁndings. The extent
of surgery has ranged fromminor procedures like hysteroscopy and di-
lation and curettage to exploratory laparotomy, total abdominal hyster-
ectomy, bilateral salpingo-oopherectomy (Shintaku and Fukushima,
2006; Olgan et al., 2011). Surgical resection is the treatment of choice.
In 90% or greater cases of IMT, excision is curative, including the amelio-
ration of associated constitutional symptoms within days or few weeks
of the resection (Rabban et al., 2005). Most patients have no recurrence
or metastasis within 5 years (Rabban et al., 2005). The 10% of patients
that recur have a large burden of disease at the onset, andwill require sur-
gical management for recurrent disease, as chemotherapy and irradiation
therapy does not seem to be of use (Cofﬁn et al., 1995). The role of hor-
monal therapy in this setting is unknown due to a paucity of literature.
The greatest clinical concern is the misdiagnosis of an IMT as an
aggressive mesenchymal neoplasm, like leiomyosarcoma or myxoid
leiomyosarcoma, since uterine IMTs appear to be indolent (Olgan
et al., 2011). IMT can be differentiated from leiomyosarcoma by a low
mitotic rate, the absence of atypical mitotic ﬁgures or nuclear atypia,
and by the absence of coagulative tumor cell necrosis. It is more difﬁcult
to differentiate IMT from myxoid leiomyosarcoma. Their morphologic
features are similar with the exception that myxoid leiomyosarcoma
has an inﬁltrative microscopic appearance; irregular tongues of tumor
invading into adjacent tissue and blood vessels (Rabban et al., 2005).
Conclusion
Although IMT has a lowmalignant potential, it is important to iden-
tify this process early as tominimize the amount of surgical intervention
needed. As in this case, had the patient been further evaluatedwhen she
ﬁrst presentedwith symptoms, the need for a total abdominal hysterec-
tomy, bilateral salpingo-oopherectomy, and tumor debulking might
have been avoided.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gynor.2013.07.007.
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